Prometheus Biosciences Inc.
RXDX | NASDAQ
$199.92
+$0.18 (+0.09%)
At close: Jun 15, 2023, 04:00 PM ET
Market Data
Market Cap $9.56B
Enterprise Value $8.87B
Beta -0.49
Average Volume N/A
Shares Outstanding (Diluted) 47.46M
Shares Change YoY 21.67%
Institutional Ownership N/A
Exchange N/A
ISIN N/A
Price Performance
Price Change 1M N/A
Price Change 3M N/A
Price Change 6M N/A
Price Change YTD N/A
Price Change 1Y N/A
Price Change 3Y N/A
Price Change 5Y N/A
1M CAGR (ann.) 2.9%
1Y CAGR (ann.) 700.3%
5Y CAGR (ann.) N/A
All-Time CAGR 149.6%
Valuation
PE Ratio -57.28
Forward PE N/A
PEG Ratio 2.75
Forward PEG 2.75
PS Ratio 2,392.62
Forward PS N/A
PB Ratio 13.70
P/FCF Ratio -70.44
P/Adj. FCF Ratio -58.77
P/OCF Ratio -65.98
EV/Sales 2,221.35
EV/EBIT -55.63
EV/EBITDA -55.25
EV/FCF -65.40
Earnings Yield -1.8%
FCF Yield -1.4%
Adj. FCF Yield -1.7%
Financial Health
Net Cash $684.21M
Total Debt $29.46M
Cash & Short-Term Investments $713.67M
Total Assets $758.41M
Current Ratio 31.04
Quick Ratio 31.08
Debt / Equity Ratio 0.04
Debt / EBITDA -0.18
Debt / FCF -0.22
OCF / Debt -4.53
Interest Coverage 0.00
Altman Z-Score 94.04
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 100.0%
Operating Profit Margin -4064.7%
EBITDA Margin -2131.7%
Net Profit Margin -2081.8%
FCF Margin -3396.4%
Adj. FCF Margin -4071.4%
SBC / Revenue 306.4%
SBC Impact (per share) -19.9%
Returns
Return on Assets -19.1%
Return on Equity -31.1%
Return on Invested Capital -20.2%
Return on Capital Employed -20.3%
Return on Tangible Assets -19.1%
Historical Growth (CAGR)
Revenue CAGR 3Y 159.7%
Revenue CAGR 5Y 57.2%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -43.9%
EPS CAGR 5Y -17.8%
EPS CAGR 10Y N/A
FCF CAGR 3Y -55.4%
FCF CAGR 5Y -22.3%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Hold
Analyst Count 11
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date Aug 9, 2023
EPS Estimate (next Q) -$0.91
EPS Growth Est (next Q) 1.1%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $138.57
Price Target Upside -30.7%
Cash Flow
Operating Cash Flow $-133.41M
Free Cash Flow $-135.69M
Adj. Free Cash Flow $-162.65M
FCF Per Share -$3.10
OCF Per Share -$3.03
OCF/S Ratio -1810.2%
Income Statement
Revenue $4M
Gross Profit $4M
Operating Income $-162.39M
EBITDA $-160.63M
Net Income $-149.13M
EPS (Diluted) -$3.49
Revenue / Employee N/A
Profit / Employee N/A
Employees N/A
Add to Watchlist
Select watchlists to add or remove RXDX